Methods for determining the risk of acute graft versus host disease

US10151745B2 · kind B2 · utility

Assignees

• Institut National de la Sante et de la Recherche Medicale (INSERM) · FR
• CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE · FR
• ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS (APHP) · FR
• UNIVERSITE DE PARIS DESCARTES · FR
• IMAGINE—INSTITUT DES MALADIES GENETIQUES NECKER ENFANTS MALADES · FR

Inventors

• Olivier Hermine · Palaiseau, FR
• Marie Thérèse Rubio · Paris, FR
• Marie Bouillie · Paris, FR
• Maria Leite de Maraes · Paris, FR

Key dates

• Filing date: Nov 21, 2013
• Grant date: Dec 11, 2018
• Expiry date: Jan 4, 2034

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/52
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

The present invention relates to a method for determining whether a candidate human transplant donor is at risk of inducing acute graft versus host disease (aGVHD) in a human transplant recipient, which may in turn allow the selection of a donor exhibiting no risk for the recipient. The present invention also relates to a method for adjusting the immunosuppressive treatment administered to a human transplanted recipient following its graft transplantation after having performing the method for determining risk of the invention. The methods comprise expanding the candidate donor's iNKT cells (invariant NKT cells) and determining the presence or absence of expansion of the CD4(−) iNKT cell sub-population. In particular, CD3+CD4− TCRV[alpha]24V[beta]11 cells are determined. Kits are disclosed.